164 related articles for article (PubMed ID: 8929158)
1. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.
Weinshenker BG; Issa M; Baskerville J
Arch Neurol; 1996 Apr; 53(4):353-8. PubMed ID: 8929158
[TBL] [Abstract][Full Text] [Related]
2. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
4. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
[TBL] [Abstract][Full Text] [Related]
5. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
Hohol MJ; Orav EJ; Weiner HL
Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
8. One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.
Hoogervorst EL; Eikelenboom MJ; Uitdehaag BM; Polman CH
J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):439-42. PubMed ID: 12640058
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
10. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
11. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
12. Clinical scales in progressive MS: predicting long-term disability.
Bosma LV; Kragt JJ; Knol DL; Polman CH; Uitdehaag BM
Mult Scler; 2012 Mar; 18(3):345-50. PubMed ID: 21868487
[TBL] [Abstract][Full Text] [Related]
13. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.
Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D
BMC Neurol; 2016 Jun; 16():83. PubMed ID: 27245221
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis relapses contribute to long-term disability.
Scott TF; Diehl D; Elmalik W; Gettings EJ; Hackett C; Schramke CJ
Acta Neurol Scand; 2019 Nov; 140(5):336-341. PubMed ID: 31314902
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
Rabadi MH; Vincent AS
Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
[TBL] [Abstract][Full Text] [Related]
17. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Signori A; Izquierdo G; Lugaresi A; Hupperts R; Grand'Maison F; Sola P; Horakova D; Havrdova E; Prat A; Girard M; Duquette P; Boz C; Grammond P; Terzi M; Singhal B; Alroughani R; Petersen T; Ramo C; Oreja-Guevara C; Spitaleri D; Shaygannejad V; Butzkueven H; Kalincik T; Jokubaitis V; Slee M; Fernandez Bolaños R; Sanchez-Menoyo JL; Pucci E; Granella F; Lechner-Scott J; Iuliano G; Hughes S; Bergamaschi R; Taylor B; Verheul F; Edite Rio M; Amato MP; Sajedi SA; Majdinasab N; Van Pesch V; Sormani MP; Trojano M
Mult Scler; 2018 Apr; 24(5):642-652. PubMed ID: 28382837
[TBL] [Abstract][Full Text] [Related]
18. Disability progression in aggressive multiple sclerosis.
Menon S; Zhu F; Shirani A; Oger J; Freedman MS; Tremlett H
Mult Scler; 2017 Mar; 23(3):456-463. PubMed ID: 27325603
[TBL] [Abstract][Full Text] [Related]
19. Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
Huda S; Cavey A; Izat A; Mattison P; Boggild M; Palace J
J Neurol Sci; 2016 Mar; 362():66-8. PubMed ID: 26944120
[TBL] [Abstract][Full Text] [Related]
20. Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis.
Margaritella N; Mendozzi L; Garegnani M; Colicino E; Gilardi E; Deleonardis L; Tronci F; Pugnetti L
Neurol Sci; 2012 Aug; 33(4):887-92. PubMed ID: 22120189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
